Pacira BioSciences, Inc. stock is down -4.32% since 30 days ago. The next earnings date is Feb 27, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 69.23% of the previous 12 November’s closed higher than October. In the last 2 Unusual Options Trades, there were 2 CALLs. 100% of analysts rate it a buy.
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectionable suspension. iovera system produces controlled doses of cold temperature only to targeted nerves.